Here, recognizing the significant growth of electronic cigarettes in recent years, the authors sought to test a hypothesis that three main components of the liquid solutions used in e-cigarettes might affect lung cancer cell viability. In a study performed by exposing A549 cells, human lung cancer cells, to different types of smoke extracts, the authors found that increasing levels of nicotine resulted in improve lung cancer cell viability up until the toxicity of nicotine resulted in cell death. They conclude that these results suggest that contrary to conventional thought e-cigarettes may be more dangerous than tobacco cigarettes in certain contexts.
Although the 5-year survival rate for colorectal cancer is below 10%, it increases to greater than 90% if it is diagnosed early. We hypothesized from our research that analyzing non-synonymous single nucleotide variants (SNVs) in a patient's exome sequence would be an indicator for high genetic risk of developing colorectal cancer.
The purpose of this study was to test the anti-cancer properties and pro-apoptotic effects of the polyherbal formulation MAT20 as a complementary treatment. Moringa oleifera (Moringa), Phyllanthus emblica (Amla) and Ocimum sanctum (Tulsi), these 3 herbs were used to formulate MAT20, which contain phytochemicals that are known to display anti-cancer properties. In this study, we hypothesized that MCF-7 breast cancer cells treated with MAT20 would show increased cytotoxicity compared to its individual plant extracts.
In this study, the authors investigate whether a new compound has anti-cancer properties. Using the crude extract from the Amaranthus spinosus plant, HeLa cancer cells were assessed for cell death. Findings reveal that the extract (AS20) has cytotoxic effects on HeLa cells. Their findings introduce a new compound to potentially pursue in the hunt for novel cancer treatments.
Here, recognizing that the immune response to cancer results in biomarkers that can be used to assess the immune status of cancer patients, the authors investigated the concentrations of key cytokines (TH1 and TH2 cytokines) in healthy controls and cancer patients. They identified significant changes in resting and activated cytokine profiles, suggesting that data of biomarkers such as these could serve as a starting point for further treatment with regard to a patient's specific immune profile.
Here, the authors chose to investigate the efficacy of zinc oxide nanoparticles (ZnO NPs) and cisplatin or zinc ions in inducing cancer apoptosis. While both treatments were found to reduce the proliferation of lung cancer cells, the authors suggest that further studies to identify the mechanism are necessary.
Treatments inhibiting Notch signaling pathways have been explored by researchers as a new approach for the treatment of glioblastoma tumors, which is a fast-growing and aggressive brain tumor. Recently, retinoic acid (RA) therapy, which inhibits Notch signaling, has shown a promising effect on inhibiting glioblastoma progression. RA, which is a metabolite of vitamin A, is very important in embryonic cellular development, which includes the regulation of multiple developmental processes, such as brain neurogenesis. However, high doses of RA treatment caused many side effects such as headaches, nausea, redness around the injection site, or allergic reactions. Therefore, we hypothesized that a combination treatment of RA and siRNA targeting NOTCH1 (siNOTCH1), the essential gene that activates Notch signaling, would effectively inhibit brain cancer cell proliferation. The aim of the study was to determine whether inhibiting NOTCH1 would inhibit the growth of brain cancer cells by cell viability assay. We found that the combination treatment of siNOTCH1 and RA in low concentration effectively decreased the NOTCH1 expression level compared to the individual treatments. However, the combination treatment condition significantly decreased the number of live brain cancer cells only at a low concentration of RA. We anticipate that this novel combination treatment can provide a solution to the side effects of chemotherapy.
The major drawback of chemotherapy regimens for treating cancer is that the cancerous cells acquire drug resistance and become impervious to further dose escalation. Keeping in mind the studied success of herbal formulations with regard to alternative treatments for cancer, we hypothesized that the use of a chemotherapeutic drug and proprietary herbal formulation, HF1, would combat this phenomenon when administered with common chemotherapeutic drug 5FU. Results demonstrated a cooperative effect between HF1 and 5FU on the drug resistant cell line, implying that administration of HF1 with 5FU results in cell death as measured by MTT assay.
The independent effects of metastasis-promoting gene CD151 in the process of metastasis are not known. This study aimed to isolate CD151 to discover what its role in metastasis would be uninfluenced by potential interactions with other components and pathways in human cells. Results showed that CD151 significantly increased the adhesion of the cells and decreased their motility. Thus, it may be that CD151 is upregulated in cancer cells for the last step of metastasis, and it increases the chances of success of metastasis by aiding in implantation of the cancer cells. Targeting CD151 in chemotherapeutic modalities could therefore potentially slow or prevent metastasis.
In this article the authors created an interaction map of proteins involved in colorectal cancer to look for driver vs. non-driver genes. That is they wanted to see if they could determine what genes are more likely to drive the development and progression in colorectal cancer and which are present in altered states but not necessarily driving disease progression.